Biotech: Page 2


  • layoff concept
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    What 3 layoff stories reveal about pharma’s troubles

    The factors driving the industry’s layoffs — and what could help turn the tide.

    By Sept. 6, 2024
  • Pfizer HQ entrance
    Image attribution tooltip
    Permission granted by Pfizer
    Image attribution tooltip

    A plucky biotech threatening Pfizer’s grip on the Prevnar vaccine market

    Results from Vaxcyte’s clinical pneumococcal vaccine study showed the smaller company could take on Pfizer’s legendary blockbuster.

    By Sept. 4, 2024
  • cancer healthcare Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Oncology

    As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

    By PharmaVoice staff
  • lab pink liquid
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma’s ‘it’ therapy — a new drug class gaining steam

    More companies are investing in protein degraders, which leverage a unique approach to harnessing the immune system in cancer, neurological diseases and more.

    By Kelly Bilodeau • Sept. 4, 2024
  • test tube dollar
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Is anyone taking the world’s priciest drugs?

    A slew of breakthrough gene therapies won FDA approval in recent years — but high price tags haven’t always yielded big returns.

    By Aug. 30, 2024
  • Wall Street buildings
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Their Alzheimer’s treatment worked — but shares fell anyway

    Cognition Therapeutics touted what the C-suite saw as a promising mid-stage study in Alzheimer’s, but investors read a different story.

    By Aug. 29, 2024
  • gloved hands cutting psilocybin mushrooms growing in a container
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    After an FDA rejection, here’s what’s next in the psychedelics pipeline

    By rejecting the first MDMA therapy earlier this month, the FDA signaled to the psychedelic drug sector that the road to approval isn’t clear cut.

    By Aug. 28, 2024
  • AI hallucination medical
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    As pharma’s AI revolution gets underway, ‘hallucinations’ pose a great risk

    While AI, machine learning and large language models can distill huge amounts of information, they sometimes make mistakes. New technologies could rebuild that trust.

    By Aug. 27, 2024
  • mpox vaccine
    Image attribution tooltip
    Mario Tama/ via Getty Images
    Image attribution tooltip

    As a new mpox strain gains ground, a key drug stumbles in the clinic

    Despite the disappointing results, the drug’s developer, Siga Therapeutics, said there’s more to the story.

    By Kelly Bilodeau • Aug. 26, 2024
  • Pill drug money balance
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Will the IRA squash new drugs? Those worries are likely exaggerated, studies say.

    There’s no link between revenue and R&D from smaller biotechs, and that’s where most innovation comes from, according to new studies.

    By Alexandra Pecci • Aug. 22, 2024
  • Workers gather inside BioMarin’s gene therapy manufacturing plant in Novato, California.
    Image attribution tooltip
    Courtesy of BioMarin Pharmaceutical
    Image attribution tooltip

    BioMarin taps Amgen, Roche vets in executive reshuffle

    Greg Friberg and James Sabry will take over, respectively, as heads of R&D and business development, less than a year after BioMarin named a new CEO.

    By Jacob Bell • Aug. 22, 2024
  • Image attribution tooltip
    Courtesy of 23andMe
    Image attribution tooltip
    Q&A

    23andMe inches closer to cancer immunotherapy, guided by its genetic database

    Dr. Jennifer Low, head of 23andMe’s therapeutics division, is taking the company into new territory with a potential cancer treatment that targets a unique pathway.

    By Aug. 20, 2024
  • Brain scan pen blood vessel
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    A biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients

    A series of executive turnovers at Gain Therapeutics this year precedes important early-stage Parkinson’s results that could change how the disease is treated.

    By Aug. 13, 2024
  • Daniel Vitt on grey backdrop
    Image attribution tooltip
    Permission granted by Immunic Therapeutics
    Image attribution tooltip

    A potential MS ‘game changer’ could bring more safety to the table — even against viruses

    Immunic’s treatment has anti-inflammation, neuroprotection and antiviral effects plus a ‘benign’ safety profile that even seems to lower the risk of COVID-19 infection.

    By Alexandra Pecci • Aug. 13, 2024
  • A Roche logo is seen on the side of a building.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs

    Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s.

    By Jacob Bell • Aug. 8, 2024
  • Graphic Abstract head and puzzle pieces against brush stroke textured background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors

    The biotech boasts some Big Pharma backers that drove a $100 million fundraising effort in July to take its depression drug into a mid-stage study.

    By Aug. 7, 2024
  • Peter Flynn, president and CEO, Arialys Therapeutics
    Image attribution tooltip
    Permission granted by Arialys Therapeutics
    Image attribution tooltip
    Biotech Spotlight

    A biotech dousing ‘fires’ in the brain that plagued a bestselling author

    Arialys Therapeutics is developing a precision medicine treatment for a rare autoimmune encephalitis that mimics psychosis.

    By Alexandra Pecci • Aug. 7, 2024
  • A product image of Moderna's RSV shot mRESVIA in its packaged box with syringe in front of the box
    Image attribution tooltip
    Permission granted by Moderna
    Image attribution tooltip

    Pfizer, GSK and Moderna execs remain optimistic about RSV vaccines despite CDC blowback

    An advisory committee’s age group recommendations look like a major setback, but executives are painting a rosier picture.

    By Aug. 6, 2024
  • James Wilson of the University of Pennsylvania
    Image attribution tooltip
    Permission granted by University of Pennsylvania
    Image attribution tooltip

    Jim Wilson, prominent gene therapy researcher, to depart UPenn

    Wilson, who founded UPenn’s gene therapy program three decades ago, will step down to start two new spinouts, Gemma Bio and Franklin Biolabs.

    By Ned Pagliarulo • Aug. 5, 2024
  • Wheelchair profile view black and white
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    In a Duchenne market beset by problems, Capricor data marks a bright spot

    The company’s cell therapy recently showed positive results from a mid-stage trial.

    By Kelly Bilodeau • Aug. 5, 2024
  • Robot hand
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Opinion

    What pharma has learned from AI

    As AI tools move from hype to a daily reality at pharma companies, here are the insights users are gaining.

    By Aug. 2, 2024
  • head shaped bookshelf filled with books on black background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Read to lead: 6 books pharma execs swear by

    From an epic, alternative reality fantasy to a ‘biography of cancer,’ these six reads have stuck with pharma execs as they navigate how to lead.

    By Alexandra Pecci • Aug. 1, 2024
  • brain on a chip
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Neuro drugs are still faltering, despite rising investment

    A brain-on-a-chip developer says better preclinical modeling could help move the needle.

    By Kelly Bilodeau • July 29, 2024
  • Biogen
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Sage’s recent trial failure adds pressure to its two-drug Biogen collab

    The mid-stage failure leaves the success of the expensive partnership hanging on a drug that’s already suffered its own setback.

    By July 29, 2024
  • pin on calendar out of focus
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Citius’ first FDA decision date is approaching — and its CEO has millions on the line

    Citius Pharmaceuticals CEO Leonard Mazur has personally invested $22.5 million into the company, which is fast approaching a potential turning point.

    By July 26, 2024
  • Ayman AlAbdallah header
    Image attribution tooltip
    Permission granted by Mubadala Capital
    Image attribution tooltip
    Q&A

    In biotech’s new market normal, here’s what’s catching this investor’s eye

    A VC investor shares how the market is recovering, which kinds of companies he’s hunting for and where he’d love to see more innovation.

    By July 25, 2024